Kingsley Biotech (01548) announced that Legend Biotech, a non-wholly-owned subsidiary of the company, was released in 2024...
Zhitong Finance App News, Kingsley Biotech (01548) announced that Legend Biotech, a non-wholly-owned subsidiary of the company, submitted Form 6-K to the US Securities Regulatory Commission (SEC) on April 22, 2024 (New York time, before the Hong Kong trading session on April 23, 2024), and the European Commission has approved CARVYKTI (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with recurrent refractory multiple myeloma. These patients have received at least one treatment before (including proteasome inhibitors (PIs) and an immunomodulator (IMID)), patients showed disease progression during the last treatment and were resistant to lenalidomide.